IP
BMY.RT

Intellectus Partners’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Intellectus Partners’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,282
Closed -$8K – 271
2020
Q4 		$8K Buy
+12,282
New +$26.2K ﹤0.01% 235
2020
Q3 		– Sell
-14,535
Closed -$52K – 242
2020
Q2 		$52K Sell
14,535
-639
-4% -$2.31K 0.02% 213
2020
Q1 		$58K Sell
15,174
-5,990
-28% -$19.7K 0.03% 188
2019
Q4 		$64K Buy
+21,164
New +$55K 0.03% 200

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $77B AUM 10.33% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $245M AUM 15.03% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Intellectus Partners's BMY.RT Position: Q1 2021 in Review

Intellectus Partners sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 12,282 shares — an estimated $8K sold.

Intellectus Partners first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $64K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Intellectus Partners reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Intellectus Partners sold 12,282 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $8K.
  • Intellectus Partners first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • Intellectus Partners's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $64K in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Intellectus Partners's 13F filing for Q1 2021, filed 17 May 2021.